Propanc Biopharma (PPCB) Non-Current Debt (2013 - 2025)
Propanc Biopharma (PPCB) posted quarterly Non-Current Debt of $65280.0 for Q4 2025, down 20.71% year-over-year from $82328.0 in Q4 2024, and down 38.2% quarter-over-quarter from $105627.0 in Q2 2025.
Propanc Biopharma (PPCB) Non-Current Debt (2013 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Non-Current Debt for 9 consecutive years, with $65280.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Debt fell 20.71% year-over-year to $65280.0; the TTM figure through Dec 2025 stood at $65280.0 (down 20.71% YoY), while the FY2025 annual figure was $105627.0, up 80.12% from the prior year.
- Non-Current Debt retreated to $65280.0 in Q4 2025 per PPCB's latest filing, from $105627.0 in the prior quarter.
- Across five years, Non-Current Debt topped out at $145091.0 in Q3 2024 and bottomed at $28581.0 in Q3 2023.
- Historically, Non-Current Debt has averaged $64443.4 across 4 years, with a median of $58642.0 in 2024.
- Annual changes were most pronounced in 2023 — Non-Current Debt slumped 30.07% — and 2024, when it jumped 407.65%.
- Propanc Biopharma's Non-Current Debt stood at $50357.0 in 2022, then plunged by 30.07% to $35214.0 in 2023, then jumped by 133.79% to $82328.0 in 2024, then decreased by 20.71% to $65280.0 in 2025.
- Business Quant data shows PPCB's Non-Current Debt at $65280.0 in Q4 2025, $105627.0 in Q2 2025, and $93913.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | 65,280.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 65,280.00 |
| Jun 30, 2025 | 105,627.00 |
| Mar 31, 2025 | 93,913.00 |
| Dec 31, 2024 | 82,328.00 |
| Sep 30, 2024 | 145,091.00 |
| Jun 30, 2024 | 58,642.00 |
| Mar 31, 2024 | 46,928.00 |
| Dec 31, 2023 | 35,214.00 |
| Sep 30, 2023 | 28,581.00 |
| Jun 30, 2023 | 65,280.00 |
| Mar 31, 2023 | 29,777.00 |
| Dec 31, 2022 | 50,357.00 |
| Jun 30, 2022 | 30,746.00 |
| Jun 30, 2018 | 54,753.00 |
| Mar 31, 2018 | 56,906.00 |
| Jun 30, 2017 | 56,802.00 |
| Dec 31, 2016 | 2,159.00 |
| Sep 30, 2016 | 2,300.00 |
| Jun 30, 2016 | 2,220.00 |
| Sep 30, 2014 | 63,196.00 |